Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases

Purpose The objective of this study was to evaluate whether uptake on 18 F-fluorodeoxyglucose ( 18 F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases. Methods In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine and molecular imaging 2024-05, Vol.58 (3), p.113-119
Main Authors: Young, Jonathan R., Ressler, Julie A., Mortimer, Joanne E., Schmolze, Daniel, Fitzgibbons, Mariko, Chen, Bihong T.
Format: Article
Language:English
Subjects:
Brain
Cardiology
Fluorine isotopes
Imaging
Lesions
Medicine
Medicine & Public Health
Nuclear Medicine
Oncology
Original
Original Article
Orthopedics
Radiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The objective of this study was to evaluate whether uptake on 18 F-fluorodeoxyglucose ( 18 F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases. Methods In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast cancer brain metastases, we analyzed both preoperative 18 F-FDG PET/CT and HER2 status of the resected/biopsied brain specimens. The maximum standardized uptake values (SUVmax) of the lesions were normalized to contralateral normal white matter and compared using Mann–Whitney U tests. Results The study cohort was comprised of 12 women with breast cancer with a mean age of 59 years (range: 43–76 years) with a total of 14 distinct brain metastatic lesions. The SUVmax ratio of HER2-positive breast cancer brain metastases was significantly greater than that of HER2-negative lesions (3.98 vs 1.79, U  = 38.00, p  = 0.008). Conclusion The SUVmax ratio may help to identify the HER2 status of breast cancer brain metastases, if validated prospectively.
ISSN:1869-3474
1869-3482
DOI:10.1007/s13139-024-00843-8